Vortex Biotech opens new state-of-the-art laboratory at Manchester Science Park
Expansion accelerates the development of its non-invasive cancer diagnostic solutions
5 Feb 2026Industry news
Vortex Biotech Holdings Limited has opened its advanced laboratory facilities at Manchester Science Park, UK. The new site significantly enhances the company’s R&D and commercial delivery capacity and strengthens its position as a leader in liquid biopsy technologies for precision oncology.
The laboratories are designed to GLP-ready specifications, allowing future expansion into clinical trial support and commercial product and services development. The site also serves as the company’s European hub for research partnerships, with planned collaborations in single-cell analysis, molecular profiling, and AI-driven data integration.
Backed by EMV Capital, Vortex’ proprietary liquid biopsy platform isolates and enriches circulating tumour cells (CTCs) and other rare biomarkers from blood samples, enabling high-sensitivity cancer detection, monitoring, and translational research. The Manchester facility will accelerate the company’s ongoing programmes in clinical validation, biomarker discovery, and commercial services development.
Nigel Brooksby, non-executive chairman at Vortex, said, "The establishment of our laboratory at Manchester Science Park is a strategic step in expanding collaborations with leading academic and clinical institutions and positions the company for growth.
"The Park’s proximity to the University of Manchester, NHS Manchester Foundation Trust, and a thriving life sciences ecosystem provides direct access to world-class expertise, clinical samples, and translational infrastructure essential for advancing liquid biopsy into clinical practice."
With this expansion, Vortex is positioned to accelerate its commercialization pathway and deliver non-invasive diagnostic solutions that improve outcomes for cancer patients worldwide.